Loyal Secures $100M Series C to Advance Canine Longevity Drug Toward Market

According to a recent LinkedIn post from Loyal, the company has closed a $100M Series C round, bringing total funding to more than $250M. The round is described as being led by age1, with participation from Baillie Gifford and existing investors.

The post indicates that the capital is intended to support the transition of LOY-002, Loyal’s lead program targeting lifespan extension in senior dogs, from late-stage development toward market readiness. The company suggests that, if approved, LOY-002 could become the first FDA-approved drug to extend lifespan in any species.

Loyal’s LinkedIn update also points to media coverage in Fast Company, where founder and CEO Celine Halioua discusses this funding milestone and the broader ambition to develop longevity drugs for dogs. For investors, the scale and caliber of investors in this round may signal growing confidence in the commercial potential of veterinary longevity therapeutics.

If LOY-002 secures FDA approval, Loyal could gain a first-mover advantage in a novel category, potentially creating a defensible market position and premium pricing power. Conversely, the focus on regulatory approval and market readiness underscores ongoing execution and clinical risk, which will likely remain a key determinant of valuation and future capital needs.